Miltefosine

Miltefosine is a broad spectrum antimicrobial, anti-leishmanial, phospholipid agent acting by inhibiting the PI3K/Akt activity[1][2][3][4]. Miltefosine is an inhibitor of CTP-phosphocholine cytidyltransferase (CCT) [5].

Product Specifications

CAS Number

[58066-85-6]

Product Name Alternative

HePC; Hexadecyl phosphocholine

UNSPSC

12352211

Hazard Statement

H301, H334

Target

Akt; HIV; Parasite

Type

Reference compound

Related Pathways

Anti-infection; PI3K/Akt/mTOR

Applications

COVID-19-anti-virus

Field of Research

Infection; Cancer

Assay Protocol

https://www.medchemexpress.com/Miltefosine.html

Purity

99.92

Solubility

DMSO : 3.33 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : 33.33 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=P(OCC[N+](C)(C)C)(OCCCCCCCCCCCCCCCC)[O-]

Molecular Formula

C21H46NO4P

Molecular Weight

407.57

Precautions

H301, H334

References & Citations

[1]Chugh P, et al. Akt inhibitors as an HIV-1 infected macrophage-specific anti-viral therapy. Retrovirology. 2008 Jan 31;5:11|[2]Uberall F, et al. Hexadecylphosphocholine inhibits inositol phosphate formation and protein kinase C activity. Cancer Res. 1991 Feb 1;51 (3) :807-12.|[3]Bhatt AP, et al. Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas. Blood. 2010 Jun 3;115 (22) :4455-63.|[4]Eissa MM, et al. Miltefosine Lipid Nanocapsules for Single Dose Oral Treatment of Schistosomiasis Mansoni: A Preclinical Study. PLoS One. 2015 Nov 17;10 (11) :e0141788|[5]de Freitas-Junior PR, et al. Effects of miltefosine on the proliferation, ultrastructure, and phospholipid composition of Angomonas deanei, a trypanosomatid protozoan that harbors a symbiotic bacterium. FEMS Microbiol Lett. 2012 Aug;333 (2) :129-37.